GEMATOLOGIYA I TRANSFUZIOLOGIYA

Scope & Guideline

Unveiling Breakthroughs in Hematology and Transfusion

Introduction

Delve into the academic richness of GEMATOLOGIYA I TRANSFUZIOLOGIYA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageRussian
ISSN0234-5730
PublisherMINISTERSTVO ZDRAVOOKHRANENIYA
Support Open AccessNo
CountryRussian Federation
TypeJournal
Convergefrom 1983 to 2024
AbbreviationGEMATOL TRANSFUZIOL / Gematol. Transfuziol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNAUCHNIY PROEZD 6, B-246 MOSCOW, RUSSIA

Aims and Scopes

The journal "GEMATOLOGIYA I TRANSFUZIOLOGIYA" focuses on hematology and transfusion medicine, aiming to disseminate knowledge and research findings that enhance the understanding and treatment of blood disorders. The journal serves as a platform for sharing advancements in clinical practices, laboratory diagnostics, and therapeutic strategies, particularly within the context of the Russian healthcare system.
  1. Clinical and Experimental Hematology:
    The journal publishes research on various hematological conditions, including leukemias, lymphomas, and other blood disorders, highlighting both clinical outcomes and experimental findings.
  2. Transfusion Medicine and Blood Safety:
    Focuses on the safety and efficacy of blood transfusions, including studies on donor screening, pathogen reduction technologies, and transfusion-related complications.
  3. Pediatric Hematology:
    Emphasizes the unique aspects of hematological diseases in children, including treatment protocols and outcomes in pediatric populations.
  4. Molecular and Genetic Research:
    Includes studies on genetic mutations, molecular markers, and their implications in hematological disorders, contributing to personalized medicine approaches.
  5. Multidisciplinary Approaches to Hematology:
    Encourages research that integrates various medical fields, such as oncology, immunology, and infectious diseases, to address the complexities of hematological conditions.
  6. Guidelines and Clinical Protocols:
    Provides a platform for the dissemination of clinical guidelines and protocols relevant to the diagnosis and management of hematological disorders.
Recent publications in "GEMATOLOGIYA I TRANSFUZIOLOGIYA" indicate a dynamic shift towards specific themes that are gaining traction. These emerging scopes reflect current challenges and advancements in the field of hematology and transfusion medicine.
  1. Impact of COVID-19 on Hematology:
    Research exploring the effects of COVID-19 on patients with hematological disorders, as well as the implications for treatment and management during the pandemic, has surged in relevance.
  2. Innovative Treatment Protocols:
    A noticeable increase in studies detailing novel treatment protocols, particularly involving targeted therapies and immunotherapies for various blood cancers.
  3. Transfusion-Related Complications and Management:
    Heightened focus on understanding and mitigating complications arising from blood transfusions, particularly in high-risk patients.
  4. Long-term Outcomes of Hematological Treatments:
    Emerging interest in studies that analyze long-term outcomes and survivorship in patients treated for hematological malignancies, emphasizing quality of life and late effects.
  5. Genetic and Molecular Profiling in Hematology:
    Growing trend towards the use of genetic and molecular profiling to inform treatment decisions and predict outcomes in hematological diseases.

Declining or Waning

As the field of hematology evolves, certain themes within the journal appear to be losing prominence. These declining scopes reflect shifts in research priorities and advancements in technology and treatment methodologies.
  1. Historical Perspectives on Hematology:
    Publications focusing on historical accounts and perspectives, such as the evolution of hematology practice or historical case studies, have seen a marked decrease.
  2. Basic Science Research without Clinical Relevance:
    There is a diminishing interest in purely laboratory-based studies that do not translate into clinical applications or impact patient care.
  3. General Reviews of Hematology:
    Broad review articles that do not focus on specific advancements or updates in the field are less frequently published, as the journal shifts towards more focused and actionable research.
  4. Epidemiological Studies of Rare Conditions:
    While still relevant, studies that focus on rare hematological conditions without a strong clinical or therapeutic focus are becoming less common in favor of more prevalent conditions.

Similar Journals

Transfusionsmedizin

Connecting clinicians and researchers in transfusion medicine.
Publisher: GEORG THIEME VERLAG KGISSN: 2191-8805Frequency: 4 issues/year

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

Journal of Blood Medicine

Empowering Research: Your Gateway to Innovations in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Blood Science

Unveiling Insights in Blood Health and Disorders
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

TRANSFUSION

Empowering Researchers in Transfusion Science
Publisher: WILEYISSN: 0041-1132Frequency: 12 issues/year

TRANSFUSION is a prestigious peer-reviewed journal published by WILEY, dedicated to advancing the field of hematology and transfusion medicine. With an ISSN of 0041-1132 and an E-ISSN of 1537-2995, this journal serves as a vital resource for researchers and professionals alike, delivering high-quality studies and reviews that impact clinical practice and blood management strategies. The journal enjoys a strong reputation, evidenced by its impressive Q1 ranking in hematology and Q2 in both immunology and allergy as of 2023. Covering foundational aspects from 1958 to 2024, TRANSFUSION not only provides valuable insights but also fosters collaboration and innovation in understanding the complexities of blood donation, transfusion practices, and immunological responses. With its significant contributions to the scientific community, this journal is essential for those seeking to stay at the forefront of research and advancements in transfusion science.

TRANSFUSION CLINIQUE ET BIOLOGIQUE

Connecting biochemistry and hematology for transformative care.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 1246-7820Frequency: 4 issues/year

TRANSFUSION CLINIQUE ET BIOLOGIQUE, an esteemed journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, has been a pivotal resource in the fields of transfusion medicine, biochemistry, and hematology since its inception in 1994. With a strong commitment to advancing scientific knowledge, this journal provides a platform for high-quality research and clinical studies aimed at improving patient care and outcomes in transfusion practices. Although categorized in Q3 and Q4 quartiles across multiple categories in Biochemistry and Medicine for 2023, the journal holds significant potential for growth and impact within the scientific community. While it currently does not offer open access options, its indexing in reputable databases ensures visibility and reach among professionals and researchers. As the field evolves, TRANSFUSION CLINIQUE ET BIOLOGIQUE aims to continue fostering innovation and collaboration, making it a valuable tool for anyone involved in medical, biochemical, and hematological research.

Turkish Journal of Hematology

Advancing hematological research for a healthier tomorrow.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

BLOOD REVIEWS

Pioneering insights into blood health and disease.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Journal of Hematology

Elevating Hematology Through Collaborative Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Hematology

Transforming Hematology: Open Access to Tomorrow's Discoveries
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

Hematology Transfusion and Cell Therapy

Pioneering insights in hematology and transfusion care.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.